Lexaria Bioscience has entered a new agreement with an unnamed pharmaceutical company to test its DehydraTECH drug delivery technology with one or more proprietary molecules supplied by the partner. This is Lexaria's third pharmaceutical collaboration, separate from two existing agreements. If initial evaluations are successful, the companies may pursue a licensing deal. The partner's identity remains confidential at their request, and Lexaria will update on progress after initial studies.
Lexaria's new pharmaceutical agreement provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 20:41 WIB: Out of 150 priced US health-sector stocks, 127 rose and 19 fell today. Notable movers include Novo Nordisk A/S (NVO) at USD 42.40 with a +5.50% change and 90% buy order activity, Amgen, Inc. (AMGN) at USD 486.50 with a +5.47% change and 68% buy order activity, and Heron Therapeutics Inc (HRTX) at USD 0.30 with a +5.37% change and 66% buy order activity. Typical hold times on Pluang range from 38 to 118 days for these stocks.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
